DRIVING GROWTH AND CREATING MARKETS FROM THE INSIDE OUT

Opportunites come from investment.

When Allergan enters a market or creates a new one, above all else it means that we intend to commit substantial resources — in research and development (R&D), physician education and patient awareness, sales and marketing, strategic acquisitions or partnerships — to grow and lead that market. While doing so, we also strive to set new standards and make meaningful contributions in areas most valued by health care specialists and their patients.

For example, this is what we did when we invested in our existing dry eye expertise to develop and commercialize our ground-breaking drug RESTASIS^® — the first, and currently only, prescription eye drop approved to address an underlying cause of chronic dry eye by increasing tear production. And it is what we are doing today in several new specialty categories.

A New Weapon in the Fight Against Obesity

In an area ripe for paradigm-changing solutions, Allergan is pioneering the market for less invasive, long-term weight-loss interventions. Allergan’s LAP-BAND^® Adjustable Gastric Banding System was the first adjustable medical device approved by the U.S. Food and Drug Administration (FDA) for individualized weight loss in a worldwide market estimated to reach $1.7 billion by 2010.⁽²⁾ The LAP-BAND^® System was the “hidden gem” in Allergan’s 2006 acquisition of Inamed Corporation. Since then Allergan has invested to increase utilization of this minimally invasive, safer and less costly approach to bariatric surgery than gastric bypass for appropriate patients. We are training surgeons, increasing patient access by securing greater reimbursement for the LAP-BAND^® System with commercial and private payors, creating specialized after-care programs to help patients following their surgery, and launching distinctive direct-to-consumer advertising and educational initiatives aimed at expanding the dialogue about obesity and its profound impact on patients’ lives.

New Standards in Medical Aesthetics

For nearly 20 years Allergan has invested in the clinical development of BOTOX^®, one of the world’s most researched and most versatile medicines. And since 2002, our development of the same product under the name BOTOX^® Cosmetic has revolutionized the global medical aesthetic marketplace.

Now the standards we set with BOTOX^® Cosmetic are being extended across the full range of Allergan’s world-leading Total Rejuvenation™ portfolio of science-based aesthetic products. In facial aesthetics, we obtained an FDA label extension for JUVÉDERM™ Ultra and JUVÉDERM™ Ultra Plus based on new clinical data demonstrating that the effects of both products may last for up to one year — making JUVÉDERM™ the only hyaluronic acid dermal filler on the market with this distinction. We also launched VIVITÉ^®, Allergan’s newest advanced skin care line that features the proprietary GLX Technology™, a formula matrix that acts as a catalyst for the penetration of glycolic acid bound with natural antioxidants to maximize the products’ anti-aging benefits.

In breast aesthetics, we are supporting the launch of the NATRELLE™ Collection of silicone- and saline-filled breast implants with enrollment of patients in our Breast Implant Follow Up Study and the launch of the Breast Implant Answers Web site. This site is a first-of-its-kind educational resource where women can access unbiased scientific information about the science and safety of silicone and silicone breast implants, provided by an independent expert group of researchers, scientists and physicians.

Today Allergan is unique in its dedication to the medical aesthetics marketplace and in the resources we provide to support product innovation, physician training and optimal patient outcomes.